ABSTRACT
Background Vincristine poses a suspected additional risk factor for hearing loss among childhood cancer survivors (CCS) treated with platinum-based chemotherapy, yet evidence is scarce since no study reports vincristine doses. We examined the association of vincristine with hearing loss in a national cohort of CCS.
Methods We included CCS registered in the Swiss Childhood Cancer Registry treated at age ≤ 18 years with platinum-based chemotherapy between 1990–2014. All participants in our retrospective cohort study had audiogram and treatment data from medical records. We identified CCS exposed to vincristine and calculated the total cumulative dose. We defined clinically relevant hearing loss as grade ≥ 2 using the International Society of Pediatric Oncology Boston Ototoxicity Scale at latest follow-up.
Results Our study population included 270 CCS (43% female; median age at cancer diagnosis 6.8 years; interquartile range [IQR]: 2.1–11.7 years) with median age at audiogram 13.5 years (IQR: 9.3–17.0 years). Vincristine exposure was associated with an increased risk of hearing loss in the multivariable logistic regression analysis (odds ratio [OR] 4.8; 95% confidence interval [CI]: 1.8–12.9). We found no evidence of dose-response relationship (OR 1.0; 95% CI: 0.97–1.04) or effect modification from vincristine from other ototoxic treatments, such as type of platinum agent, cranial radiotherapy, and hematopoietic stem cell transplantation.
Conclusion Vincristine is associated with a higher risk of hearing loss in CCS treated with platinum-based chemotherapy. We suggest future studies investigate the underlying mechanism and causality among CCS without exposure to other ototoxic cancer treatments.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the Swiss Cancer League (HSR-4951-11-2019), the CANSEARCH Foundation (https://cansearch.ch/), and the European Union Seventh Framework Program for research, technological development and demonstration under grant agreement no. 602030. The EU Commission takes no responsibility for any use made of the information set out. Further funding comes from Swiss Cancer Research (KLS/KFS-4825-01-2019, KFS-5027-02-2020) and Kinderkrebshilfe Schweiz (https://www.kinderkrebshilfe.ch/de).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Ethics Committee of the Canton of Bern approved the SCCR and the Swiss Childhood Cancer Survivor Study (KEK-BE: 166/2014; 2021-01462).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data that support the information of this manuscript were accessed on secured servers of the Institute of Social and Preventive Medicine at the University of Bern. Individual-level sensitive data can only be made available for researchers who fulfil the respective legal requirements. All data requests should be communicated to the corresponding author.
